Associated Alcohols challenges FSSAI directive affecting whisky and rum brand sales

Associated Alcohols & Breweries has moved the High Court against an FSSAI pan-India directive that bars sale of a whisky and rum brand over artificial-flavour labelling. The company is assessing the operational and financial impact as alcohol-industry bodies dispute the regulator’s interpretation.

— Source publishedFri, 31 Jul, 2026, 13:06 IST·First seen Fri, 31 Jul, 2026, 13:13 IST·Source The Hindu BusinessLine

What happened

Associated Alcohols & Breweries Ltd · Associated Alcohols & Breweries has moved the High Court against FSSAI’s pan-India directive barring sale of a whisky and

Key facts

  • Food Safety and Standards (Labelling and Display) Regulations, 2020

Why this matters

Treat regulatory interpretation of flavour labelling as a diligence priority in spirits partnerships or acquisitions, given its potential to impair brand-market access.

What to watch

  • High Court decision on an interim stay, including whether existing inventory may continue to be sold.
  • FSSAI affidavit or clarification defining the allegedly non-compliant artificial-flavour labelling practice.
  • Identification of the affected brands, their revenue contribution, and the number of states where distribution is interrupted.
  • Any enforcement notices, product seizures, recall directions, or state excise actions.
  • Peer-company disclosures showing whether the directive affects a broader set of whisky and rum products.
  • Company commentary on inventory provisions, sales disruption, relabelling timelines, and guidance changes.
  • Seek interim judicial relief and challenge FSSAI's interpretation of flavour-labelling rules.
  • Suspend or ring-fence affected inventory and shipments in states where enforcement risk is highest.
  • Prepare revised labels, regulatory filings, and potentially reformulated stock to shorten the restart period.
  • Engage alcohol-industry bodies and state excise authorities for a harmonized compliance position.
  • Quantify exposure from lost sales, distributor claims, inventory provisions, and incremental packaging or legal costs in upcoming disclosures.